Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live-attenuated dengue virus 3 monovalent vaccine
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The live-attenuated dengue virus 3 monovalent vaccine (specifically strain rDEN3Δ30/31-7164) is an investigational prophylactic vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID). It is derived from the wild-type DENV-3 Sleman/78 virus and contains 30 and 31 non-contiguous nucleotide deletions in the 3' untranslated region (UTR) for attenuation, along with a Vero cell adaptation mutation in the NS4B gene (position 7164, Val→Ala). This monovalent vaccine is designed to elicit protective neutralizing antibodies and cellular immune responses against dengue virus serotype 3. It is also utilized as a component of the investigational tetravalent dengue vaccine TV003 and as a controlled human challenge model to study primary, secondary, and tertiary dengue immune responses.
- Other names
- live-attenuated DENV3 monovalent vaccine
Beyond the preview
Go deeper on live-attenuated dengue virus 3 monovalent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live-attenuated dengue virus 3 monovalent vaccine.